Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online Oct. 14 ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...

Lenacapavir is a long-acting injectable drug that has proven 100 per cent successful in clinical tests and subsequent human ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...

(HealthDay News) — Preexposure prophylaxis (PrEP) use increased between 2013 and ... Generic TDF/FTC reached the highest monthly share of users among all medications from December 2021 to December ...

Hispanic Americans accounted for 33% of estimated new HIV infections ... post-exposure prophylaxis. The experts added that having more Hispanics and Latinos represented in medicine, research ...

Those who take post-exposure prophylaxis (PEP) — an anti-HIV medicine — within 72 hours of exposure may avoid becoming infected at all. For those who are infected, no cure is available for HIV.

Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...